NYSE:CBM - Cambrex Stock Price, Price Target & More

$54.70 -0.30 (-0.55 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$55.00
Today's Range$54.25 - $55.75
52-Week Range$42.55 - $62.95
Volume154,411 shs
Average Volume299,936 shs
Market Capitalization$1.81 billion
P/E Ratio17.26
Dividend YieldN/A
Beta2.32

About Cambrex (NYSE:CBM)

Cambrex logoCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.11%
Quick Ratio3.44%

Price-To-Earnings

Trailing P/E Ratio17.26
Forward P/E Ratio19.47
P/E Growth1.3

Sales & Book Value

Annual Sales$534.46 million
Price / Sales3.36
Cash Flow$4.1916 per share
Price / Cash13.05
Book Value$16.62 per share
Price / Book3.29

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins19.17%
Return on Equity22.42%
Return on Assets15.91%

Miscellaneous

Employees1,228
Outstanding Shares32,850,000

How to Become a New Pot Stock Millionaire

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.17. The biotechnology company earned $182.28 million during the quarter, compared to analyst estimates of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. Cambrex's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex issued an update on its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $2.80-3.03 for the period, compared to the Thomson Reuters consensus estimate of $2.85. The company issued revenue guidance of $524-545 million (Down 2% to Up 2%), compared to the consensus revenue estimate of $538.50 million.

What price target have analysts set for CBM?

3 brokerages have issued twelve-month price objectives for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next year. View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)
  • Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)

Has Cambrex been receiving favorable news coverage?

News articles about CBM stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cambrex earned a media sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $54.70.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.81 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (CBM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cambrex (NYSE:CBM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Cambrex in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 9.69%. The high price target for CBM is $60.00 and the low price target for CBM is $60.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.00$60.00$60.50$65.6667
Price Target Upside: 9.69% upside9.19% upside17.13% upside16.64% upside

Cambrex (NYSE:CBM) Consensus Price Target History

Price Target History for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Longbow ResearchDowngradeBuy -> NeutralMediumView Rating Details
1/16/2018William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
10/31/2017Craig HallumReiterated RatingBuy$70.00 -> $60.00N/AView Rating Details
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Cambrex (NYSE:CBM) Earnings History and Estimates Chart

Earnings by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.47$0.47$0.47
Q2 20181$0.74$0.74$0.74
Q3 20181$0.57$0.57$0.57

Cambrex (NYSE CBM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.51N/AView Earnings Details
2/8/2018Q4 2017$1.10$1.27$181.39 million$182.28 millionViewN/AView Earnings Details
11/7/2017Q3 2017$0.47$0.55$108.44 million$112.60 millionViewN/AView Earnings Details
8/4/2017Q2 2017$0.76$0.76$136.82 million$134.55 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
11/3/2010Q3 2010$0.09$0.02ViewN/AView Earnings Details
8/3/2010Q2 2010$0.11$0.12ViewN/AView Earnings Details
5/4/2010Q1 2010$0.11$0.06ViewN/AView Earnings Details
2/10/2010Q4 2009$0.05($0.09)ViewN/AView Earnings Details
11/3/2009Q3 2009$0.05$0.10ViewN/AView Earnings Details
8/4/2009Q2 2009$0.10$0.19ViewN/AView Earnings Details
5/5/2009Q1 2009$0.09$0.16ViewN/AView Earnings Details
2/11/2009Q4 2008$0.09$0.05ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.10ViewN/AView Earnings Details
8/5/2008Q2 2008$0.12$0.08ViewN/AView Earnings Details
5/1/2008Q1 2008$0.14$0.16ViewN/AView Earnings Details
2/14/2008Q4 2007$0.13$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cambrex (NYSE:CBM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.42%
Insider Trading History for Cambrex (NYSE:CBM)
Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017Steven M KloskCEOSell4,000$54.96$219,840.0087,328View SEC Filing  
9/1/2017Steven M KloskCEOSell12,000$51.53$618,360.0095,328View SEC Filing  
8/1/2017Steven M KloskCEOSell12,000$61.39$736,680.0095,328View SEC Filing  
7/3/2017Steven M KloskCEOSell12,000$59.66$715,920.0095,328View SEC Filing  
6/12/2017Samantha HanleyVPSell14,000$57.56$805,840.001,500View SEC Filing  
6/6/2017Leon J Hendrix JrDirectorSell20,656$55.95$1,155,703.2074,662View SEC Filing  
6/1/2017Steven M KloskCEOSell12,000$54.19$650,280.0095,328View SEC Filing  
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.0095,328View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.0095,328View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.0095,328View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.0017,658View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.0094,241View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90109,062View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.0050,000View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.6057,658View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.0027,658View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.0027,500View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.0023,982View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.7424,704View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.0025,304View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00147,333View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90136,828View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.0032,562View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00152,893View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00928View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.0032,562View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.5246,697View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.4617,658View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40133,328View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.0071,211View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.3221,520View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.8060,000View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.0033,319View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.0046,562View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.0092,993View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.0067,085View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.0033,319View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.0035,306View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cambrex (NYSE CBM) News Headlines

Source:
DateHeadline
Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC FacilityCambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
finance.yahoo.com - April 23 at 8:47 AM
Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance PracticesCambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices
finance.yahoo.com - April 19 at 5:01 PM
vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setbackvTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
www.bizjournals.com - April 18 at 9:01 AM
Cambrex Co. (CBM) Expected to Post Quarterly Sales of $110.80 MillionCambrex Co. (CBM) Expected to Post Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 18 at 3:04 AM
Cambrex Invests in New Continuous Flow Technology at its High Point, NC FacilityCambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
finance.yahoo.com - April 17 at 9:18 AM
Cambrex Co. (CBM) Expected to Announce Earnings of $0.31 Per ShareCambrex Co. (CBM) Expected to Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - April 16 at 1:12 PM
Cambrex, poised for another expansion, buys two properties for $10.2MCambrex, poised for another expansion, buys two properties for $10.2M
www.bizjournals.com - April 16 at 8:55 AM
Cambrex (CBM) Lifted to Hold at Zacks Investment ResearchCambrex (CBM) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:43 PM
Cambrex (CBM) Upgraded to Buy at ValuEngineCambrex (CBM) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 10 at 9:17 AM
Cambrex Co. (CBM) Receives Consensus Recommendation of "Hold" from BrokeragesCambrex Co. (CBM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 8 at 1:30 AM
Cleantech Building Materials: Notice of AGMCleantech Building Materials: Notice of AGM
finance.yahoo.com - April 3 at 4:54 PM
Cambrex (CBM) Rating Reiterated by Craig HallumCambrex (CBM) Rating Reiterated by Craig Hallum
www.americanbankingnews.com - April 2 at 8:04 PM
Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $110.80 MillionCambrex Co. (CBM) Expected to Announce Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 1 at 2:54 AM
Zacks: Brokerages Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.31 Per ShareZacks: Brokerages Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM
Cleantech Building Materials: Annual Results to 31 December 2017Cleantech Building Materials: Annual Results to 31 December 2017
finance.yahoo.com - March 29 at 9:16 AM
Cambrex (CBM) Downgraded to Sell at Zacks Investment ResearchCambrex (CBM) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
Cleantech Building Materials: Application to Wiener BörseCleantech Building Materials: Application to Wiener Börse
finance.yahoo.com - March 16 at 9:11 AM
Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%
finance.yahoo.com - March 16 at 9:11 AM
Should Value Investors Pick Cambrex (CBM) Stock?Should Value Investors Pick Cambrex (CBM) Stock?
finance.yahoo.com - March 15 at 5:25 PM
$110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter$110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter
www.americanbankingnews.com - March 15 at 4:58 AM
Cambrex Co. (CBM) Given Consensus Rating of "Hold" by AnalystsCambrex Co. (CBM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 14 at 1:54 AM
Zacks: Analysts Anticipate Cambrex Co. (CBM) to Post $0.31 Earnings Per ShareZacks: Analysts Anticipate Cambrex Co. (CBM) to Post $0.31 Earnings Per Share
www.americanbankingnews.com - March 13 at 12:50 PM
Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P.Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P.
www.americanbankingnews.com - March 5 at 3:37 PM
Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM)Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM)
www.americanbankingnews.com - March 5 at 11:11 AM
Cambrex Co. (CBM) Shares Sold by Bank of New York Mellon CorpCambrex Co. (CBM) Shares Sold by Bank of New York Mellon Corp
www.americanbankingnews.com - March 5 at 5:00 AM
Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc.Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 3 at 3:30 PM
Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM)Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM)
www.americanbankingnews.com - March 3 at 9:12 AM
Cambrex Co. (CBM) Stake Lessened by King Luther Capital Management CorpCambrex Co. (CBM) Stake Lessened by King Luther Capital Management Corp
www.americanbankingnews.com - March 2 at 12:33 PM
AlphaOne Investment Services LLC Reduces Stake in Cambrex Co. (CBM)AlphaOne Investment Services LLC Reduces Stake in Cambrex Co. (CBM)
www.americanbankingnews.com - February 26 at 5:14 AM
Cambrex Co. (CBM) Shares Bought by Pinebridge Investments L.P.Cambrex Co. (CBM) Shares Bought by Pinebridge Investments L.P.
www.americanbankingnews.com - February 25 at 9:30 AM
Cleantech Building Materials: APPOINTMENT OF FINANCIAL ADVISER AND BROKERCleantech Building Materials: APPOINTMENT OF FINANCIAL ADVISER AND BROKER
finance.yahoo.com - February 20 at 5:15 PM
Contrasting Cambrex (CBM) & Veru (VERU)Contrasting Cambrex (CBM) & Veru (VERU)
www.americanbankingnews.com - February 18 at 12:08 PM
Cambrex Co. (CBM) Receives Average Rating of "Hold" from BrokeragesCambrex Co. (CBM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 17 at 1:48 AM
Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceCambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 8:26 AM
Cambrex (CBM) Downgraded by Longbow ResearchCambrex (CBM) Downgraded by Longbow Research
www.americanbankingnews.com - February 15 at 12:52 AM
First Analysis Weighs in on Cambrex Co.s Q3 2018 Earnings (CBM)First Analysis Weighs in on Cambrex Co.'s Q3 2018 Earnings (CBM)
www.americanbankingnews.com - February 13 at 10:18 AM
Cleantech Building Materials: Thailand Distribution and Offtake AgreementCleantech Building Materials: Thailand Distribution and Offtake Agreement
finance.yahoo.com - February 9 at 9:30 AM
Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular LymphomaBlog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma
finance.yahoo.com - February 9 at 9:30 AM
Zacks: Brokerages Expect Cambrex Co. (CBM) Will Announce Quarterly Sales of $184.15 MillionZacks: Brokerages Expect Cambrex Co. (CBM) Will Announce Quarterly Sales of $184.15 Million
www.americanbankingnews.com - February 9 at 2:14 AM
Cleantech Building Materials: Amendment of Loan FacilityCleantech Building Materials: Amendment of Loan Facility
finance.yahoo.com - February 8 at 4:06 PM
Cambrex beats 4Q profit forecastsCambrex beats 4Q profit forecasts
finance.yahoo.com - February 8 at 4:06 PM
Is It Time To Buy Cambrex Corporation (NYSE:CBM)?Is It Time To Buy Cambrex Corporation (NYSE:CBM)?
finance.yahoo.com - February 8 at 4:06 PM
Cambrex (CBM) Issues Quarterly  Earnings ResultsCambrex (CBM) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 8 at 10:58 AM
Cambrex (CBM) Updates FY18 Earnings GuidanceCambrex (CBM) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 8 at 9:00 AM
Cambrex Reports Fourth Quarter and Full Year 2017 Financial ResultsCambrex Reports Fourth Quarter and Full Year 2017 Financial Results
feeds.benzinga.com - February 8 at 7:45 AM
Cambrex beats by $0.15, misses on revenueCambrex beats by $0.15, misses on revenue
seekingalpha.com - February 8 at 6:49 AM
Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018
finance.yahoo.com - February 2 at 9:28 AM
Estimating The Intrinsic Value Of Cambrex Corporation (NYSE:CBM)Estimating The Intrinsic Value Of Cambrex Corporation (NYSE:CBM)
finance.yahoo.com - February 1 at 4:07 PM
Cambrex Expands Process Research and Development Capabilities Across North AmericaCambrex Expands Process Research and Development Capabilities Across North America
finance.yahoo.com - January 30 at 9:59 AM
Cambrex (CBM) Set to Announce Earnings on ThursdayCambrex (CBM) Set to Announce Earnings on Thursday
www.americanbankingnews.com - January 25 at 1:44 AM

SEC Filings

Cambrex (NYSE:CBM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cambrex (NYSE CBM) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.